93.53
2.96 (3.27%)
| Penutupan Terdahulu | 90.57 |
| Buka | 91.39 |
| Jumlah Dagangan | 757,736 |
| Purata Dagangan (3B) | 1,530,346 |
| Modal Pasaran | 4,576,601,088 |
| Harga / Buku (P/B) | 78.90 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 Nov 2026 |
| EPS Cair (TTM) | -3.05 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 113.89% |
| Nisbah Semasa (MRQ) | 6.61 |
| Aliran Tunai Operasi (OCF TTM) | -102.25 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -62.83 M |
| Pulangan Atas Aset (ROA TTM) | -39.04% |
| Pulangan Atas Ekuiti (ROE TTM) | -115.39% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Celcuity Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | 1.5 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -1.0 |
| Purata | 0.63 |
|
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company’s lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 13.21% |
| % Dimiliki oleh Institusi | 81.78% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| HAHNE VICKY | 92.00 | - | 16,000 | 1,472,000 |
| LAING LANCE G. | 92.00 | - | 20,000 | 1,840,000 |
| SULLIVAN BRIAN F. | 92.00 | - | 80,000 | 7,360,000 |
| Jumlah Keseluruhan Kuantiti Bersih | 116,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 10,672,000 | |||
| Purata Pembelian Keseluruhan ($) | 92.00 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| HAHNE VICKY | Pegawai | 14 Aug 2026 | Diperolehi (+) | 16,000 | 92.00 | 1,472,000 |
| SULLIVAN BRIAN F. | Pegawai | 14 Aug 2026 | Diperolehi (+) | 80,000 | 92.00 | 7,360,000 |
| LAING LANCE G. | Pegawai | 14 Aug 2026 | Diperolehi (+) | 20,000 | 92.00 | 1,840,000 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |